Comparison of the effect of unilateral intravitreal bevacizumab and ranibizumab injection on diabetic macular edema of the fellow eye

Journal of Ocular Pharmacology and Therapeutics

Volumn 29, Issue 8, 2013, Pages 728-732

  Bakbak, Berker ^a   Ozturk, Banu Turgut ^a   Gonul, Saban ^a   Yilmaz, Mevlut ^a   Gedik, Sansal ^a  

^a SELCUK UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; HEMOGLOBIN A1C; RANIBIZUMAB;

ADULT; ARTICLE; CENTRAL FOVEAL THICKNESS; COMPARATIVE STUDY; CONTROLLED STUDY; DIABETIC MACULAR EDEMA; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; INTRAOCULAR PRESSURE; MACULAR THICKNESS; MAJOR CLINICAL STUDY; MALE; OPTICAL COHERENCE TOMOGRAPHY; RETROSPECTIVE STUDY; VISUAL ACUITY; VISUAL SYSTEM PARAMETERS;

ANTIBODIES, MONOCLONAL, HUMANIZED; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; INTRAVITREAL INJECTIONS; MACULAR EDEMA; MALE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84885002110     PISSN: 10807683     EISSN: 15577732     Source Type: Journal    
DOI: 10.1089/jop.2013.0049     Document Type: Article

References (24)

1. Witkin, A.J., and Brown, G.C. Update on nonsurgical therapy for diabetic macular edema. Curr. Opin. Ophthalmol. 22:185-189, 2011
2. Zechmeister-Koss, I., and Huic, M. Vascular endothelial growth factor inhibitors (anti-VEGF) in the management of diabetic macular oedema: a systematic review. Br. J. Ophthalmol. 96:167-178, 2012
3. Velez-Montoya, R., Fromow-Guerra, J., Burgos, O., et al. The effect of unilateral intravitreal bevacizumab (avastin), in the treatment of diffuse bilateral diabetic macular edema: a pilot study. Retina. 29:20-26, 2009
4. Scartozzi, R., Chao, J.R., Walsh, A.C., and Eliott, D. Bilateral improvement of persistent diffuse diabetic macular oedema after unilateral intravitreal bevacizumab (Avastin) injection. Eye (Lond.). 23:1229, 2009
5. Ozturk, B.T., Kerimoglu, H., Bozkurt, B., and Okudan, S. Comparison of intravitreal bevacizumab and ranibizumab treatment for diabetic macular edema. J. Ocul. Pharmacol. Ther. 27:373-377, 2011
6. Goyal, S., Lavalley, M., and Subramanian, M.L. Meta-analysis and review on the effect of bevacizumab in diabetic macular edema. Graefes Arch. Clin. Exp. Ophthalmol. 249:15-27, 2011
7. Arevalo, J.F., and Garcia-Amaris, R.A. Intravitreal bevacizumab for diabetic retinopathy. Curr. Diabetes Rev. 5:39-46, 2009
8. Chun, D.W., Heier, J.S., Topping, T.M., Duker, J.S., and Bankert, J.M. A pilot study of multiple intravitreal injections of ranibizumab in patients with center-involving clinically significant diabetic macular edema. Ophthalmology. 113: 1706-1712, 2006
9. Ozsutcu, M., Gulkilik, G., Ayintap, E., et al. Intravitreal bevacizumab may increase diabetic macular edema in eyes with attached posterior vitreous. Case Rep. Ophthalmol. 4:7-10, 2013
10. Krohne, T.U., Liu, Z., Holz, F.G., and Meyer, C.H. Intraocular pharmacokinetics of ranibizumab following a single intravitreal injection in humans. Am. J. Ophthalmol. 154:682-686, 2012
11. Bakri, S.J., Snyder, M.R., Reid, J.M., et al. Pharmacokinetics of intravitreal ranibizumab (Lucentis). Ophthalmology. 114: 2179-2182, 2007
12. Zehetner, C., Kirchmair, R., Huber, S., Kralinger, M.T., and Kieselbach, G.F. Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema. Br. J. Ophthalmol. 97:454-459, 2013
13. Wu, Z., and Sadda, S.R. Effects on the contralateral eye after intravitreal bevacizumab and ranibizumab injections: a case report. Ann. Acad. Med. Singapore. 37:591-593, 2008
14. Al-Dhibi, H., and Khan, A.O. Bilateral response following unilateral intravitreal bevacizumab injection in a child with uveitic cystoid macular edema. J. AAPOS. 13:400-402, 2009
15. IVAN Study Investigators, Chakravarthy, U., and Harding, S.P. Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology. 119:1399-1411, 2012
16. Bakri, S.J., Snyder, M.R., Reid, J.M., Pulido, J.S., and Singh, R.J. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology. 114:855-859, 2007
17. Avery, R.L., Pearlman, J., Pieramici, D.J., et al. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology. 113:1695.e1-e15, 2006
18. Barbazetto, I.A., Saroj, N., Shapiro, H., et al. Incidence of new choroidal neovascularization in fellow eyes of patients treated in the MARINA and ANCHOR trials. Am. J. Ophthalmol. 149:939-946, 2010
19. Gamulescu, M.A., and Helbig, H. Lack of therapeutic effect of ranibizumab in fellow eyes after intravitreal administration. J. Ocul. Pharmacol. Ther. 26:213-216, 2010
20. Acharya, N.R., Sittivarakul, W., Qian, Y., Hong, K.C., and Lee, S.M. Bilateral effect of unilateral ranibizumab in patients with uveitis-related macular edema. Retina. 31:1871-1876, 2011
21. Rouvas, A., Liarakos, V.S., Theodossiadis, P., et al. The effect of intravitreal ranibizumab on the fellow untreated eye with subfoveal scarring due to exudative age-related macular degeneration. Ophthalmologica. 223:383-389, 2009
22. Michels, S., Rosenfeld, P.J., Puliafito, C.A., Marcus, E.N., and Venkatraman, A.S. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelveweek results of an uncontrolled open-label clinical study. Ophthalmology. 112:1035-1047, 2005
23. Nwanze, C.C., Akinwale, A., and Adelman, R.A. Clinical medicine insights. Therapeutics 4:29-38, 2012
24. Wong, T.Y., Liew, G., and Mitchell, P. Clinical update: new treatments for age-related macular degeneration. Lancet. 370:204-206, 2007.